Latest Articles
-
Abbott Posts Broadly Positive Results, Currency Headwinds Notwithstanding
Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $5.2 billion, an increase of 2.2% as reported or 10.7% on an operational (constant currency) basis. Adjusting for both currency effects and acquisitions, sales were up by a respecta...
-
How Abbott Sees Potential Gains In Boosting Mylan In Perrigo Takeover Fight ?
Abbott Laboratories (NYSE:ABT) has been on the roll in recent months. March-period earnings were strong, where the worldwide operational sales increased 10% year over year to $4.9 billion with robust growth experience in emerging markets, as we n...
-
Abbott Labs Q1 2015 Earnings: Emerging Markets Drive Growth Across Divisions
Abbott Laboratories (NYSE:ABT) reported another strong quarter on Wednesday, April 22. The company’s worldwide operational sales increased 10% year over year to $4.9 billion with robust growth experienced in emerging markets. The sale of Ab...
-
Abbott Reports Solid Q4 Results On Growth Across Divisions
Healthcare major Abbott Laboratories (NYSE:ABT) reported a strong set of fourth quarter 2014 results on Thursday, January 29. The company’s operational sales from continuing operations increased 10.2% over the prior year quarter to $5.4 bi...
-
Abbott’s Generic Drug Business Gets A Boost With Veropharm Acquisition
Global healthcare major Abbott Laboratories (NYSE:ABT) has completed its acquisition of Russian pharmaceutical company Veropharm for 16.7 billion rubles ($305 million) in an all-cash deal. Veropharm is one of the leading generic drug manufacture...
-
Abbott Looking To Electrophysiology For Medical Device Growth
Abbott Laboratories (NYSE:ABT) recently expanded its medical device business and entered the fast-growing catheter-based electrophysiology market with the acquisition of Topera, Inc. Last month, Abbott entered into an agreement to buy the medical...
-
Abbott Reports Solid Q3 Results On Nutritionals Recovery, Emerging Markets
Healthcare major Abbott Laboratories (NYSE:ABT) reported a strong set of third quarter 2014 results on Wednesday, October 22. The company’s sales from continuing operations increased 6.7% over the prior year quarter to $5.1 billion. Abbott...
-
Abbott Earnings Preview: Nutritionals, Emerging Markets In Focus
Abbott Labs (NYSE:ABT) is scheduled to release its Q3 earnings on Wednesday, October 22. In the previous quarter, operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts’ estimates of $5.52 billion comp...
-
Abbott Looks To Boost Vision Care Product Sales With New Plant In Malaysia
Abbott Laboratories (NYSE:ABT) recently announced that it will invest $60 million in an intraocular lens (IOL) manufacturing plant in Malaysia. IOLs are lenses which are implanted in the eye during the treatment of cataracts. The company expects ...
-
Abbott’s Collaboration With Department Of Defense Could Boost Diagnostics Sales
Abbott Laboratories (NYSE:ABT) recently announced a collaboration with the United States Department of Defense (DoD) to develop portable blood tests for the evaluation of mild traumatic brain injuries (TBIs). The tests would be specifically devel...
-
Abbott Raises Full Year Earnings Guidance On Strong Q2 Results
Healthcare giant Abbott Laboratories (NYSE:ABT) reported a strong set of second quarter 2014 results on Wednesday, July 16. The company’s operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts’ ...
-
Abbott Streamlines Generic Drug Business With Sale Of Developed Market Assets To Mylan
Global healthcare major Abbott Laboratories (NYSE:ABT) has entered into an agreement to sell a part of its generic drug business to specialty pharmaceuticals company Mylan (NASDAQ:MYL) in an all-stock deal. Mylan will acquire Abbott’s gene...
-
Abbott Earnings Preview: Recovery In Nutritionals, Growth In Emerging Markets To Drive Sales
Abbott Labs (NYSE:ABT) is scheduled to release its Q2 2014 earnings on Wednesday, July 16. In the previous quarter, sales declined by 2.5% year-over-year (y-o-y) to $5.24 billion, owing to sustained weakness in the Nutritionals and Established Ph...
-
Abbott Eyeing Growth In European Cataract Surgery Market With New Approval
Global healthcare giant Abbott Laboratories (NYSE:ABT) has received CE approval for its TECNIS Symfony extended range of vision intraocular lenses (IOL), used for the treatment of cataract patients who may also have difficulty focusing on close o...
-
Abbott Acquires Veropharm To Expand Presence In Russia
Global healthcare major Abbott Laboratories (NYSE:ABT) has agreed to acquire Russian pharmaceutical company Veropharm for between 13.6 billion and 17 billion rubles ($395 million – $495 million) in an all-cash deal. Veropharm is one of the ...
